MANILA, April 8 (Reuters) - Philippine health authorities
suspended on Thursday the use of Astrazeneca 's AZN.L COVID-19
vaccine for people below 60 years of age to investigate reports
of blood clots coming from overseas.
The temporary suspension came after the European Medicines
Agency recommended to include blood clots as a rare side effect
of the vaccine, Food and Drug Administration chief Rolando
Enrique Domingo said in a statement, adding that there were no
reports of such adverse side effects in the country.
The Philippines has so far received 525,600 doses of
AstraZeneca (NASDAQ:AZN)'s vaccines, about a fifth of the country's total
inventory, through the COVAX facility.